Moleculin BiotechCompletes IPO; MBRX Shares Set to Commence Trading on NASDAQ Capital Market June 2, 2016; the company will use the net proceeds of the offering to commence a further Phase II of Annamycin in treating AML
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|MBRX||Community voting in process|
The Company plans to use the net proceeds of the offering to commence a further Phase II clinical trial for Annamycin, an anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. Other uses of the MBRX IPO funding include license maintenance and IP prosecution costs, research, and general working capital purposes.
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?